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Recommendations for the age to initiate cervical cancer screening
should be directed towards maximum detection of early cervical
cancer. However, the screening programme should do more good
than harm. The aim of this analysis was to determine whether the
target age for cervical cancer screening should be lowered in view
of apparent increases in new cases of invasive cancer below age 30
and in age group 30–44 years in The Netherlands. Therefore, all
cervical cancer cases diagnosed between January 1, 1989 and De-
cember 31, 2003 were selected from the nationwide population-
based Netherlands Cancer Registry. For age group 25–39 years,
incidence data were also available for 2004 and 2005. To describe
trends, the estimated annual percentage of change and joinpoint
analysis were used. Between ages 25 and 28 years, the absolute
number of new cases of cervical cancer annually has varied
between 0 and 9 per age. Significantly decreasing trends in inci-
dence were observed for age groups 35–39 and 45–49 (p < 0.0001
and p 5 0.01, respectively). The annual number of deaths fluctu-
ated with a decreasing trend for age groups 30–34 and 35–39 years
(p 5 0.01 and p 5 0.03, respectively). Because the incidence and
mortality rates for cervical cancer among women younger than 30
are low and not increasing, lowering the age for cervical cancer
screening is not useful at this time. Although the number of years
of life gained is high for every case of cervical cancer prevented,
the disadvantages of lowering the screening age would be very
large and even become disproportionate compared to the potential
advantages.
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Mass screening for cervical cancer has been performed in sev-
eral countries with varying success. Success depends on the cover-
age and intensity of the screening, such as intervals between tests,
age groups covered, attendance rate, quality of laboratories, qual-
ity of follow-up after a positive test and coordination of organized
and opportunistic screening.1–3 The objective of cervical cancer
screening is to prevent the occurrence of and death from cervical
cancer by detecting intraepithelial lesions (ASCUS) and treating
high-grade preinvasive lesions (HSIL). However, it remains im-
portant that the screening programme should do more good than
harm, as was also described by Wilson and Jungner.4
It is now well established that human papillomavirus (HPV)
infection is the central causal factor in cervical cancer.5 HPV is a
common sexually transmitted infection, and both women and men
are usually exposed to the virus after the onset of sexual inter-
course. The risk of infection with HPV and also the risk of cervi-
cal cancer increase with the number of sexual partners, lower age
at first sexual activity and number of sexual partners of male part-
ners.6 Additional risk indicators for cervical cancer are the number
of live births, long-term use of oral contraceptives, cigarette smok-
ing and immuno-suppression.7
The prevalence of HPV infections and, as a result, cytological
abnormalities in sexually active young women is high: 80% of all
women eventually have an HPV infection, with peak prevalence
between ages 25 and 29.8 HPV acquisition generally decreases
with increasing age and HPV persistence increases with age.9 The
higher acquisition in younger women may be due to their higher
sexual activity; the reasons for higher persistence among older
patients are not clear. However, although 10% to 20% of HPV
infections develop into precancerous lesions, most of these cases
will clear spontaneously: the likelihood of regression of low-grade
preinvasive lesions (LSIL) is 60% while the risk of progression to
invasion is 1%. The likelihood that HSIL will regress is 33–40%
while progression to invasion is seen in more than 12% of cases.10
An observational study published in 2003 confirms that 80% of
high grade dyskaryosis and dysplasia cannot be destined to pro-
gress in a woman’s lifetime.11 In The Netherlands, referral to the
gynaecologist takes place after repeated borderline findings [atyp-
ical squamous cells of undetermined significance (ASCUS) or
LSIL] or after clearly positive cytology (HSIL).
Incidence and mortality rates are low and decreasing in The
Netherlands (World Standardized Rates 4.9 and 1.2 per 100,000
woman-years in 2003, respectively12,13). Screening for cervical
cancer was started in the mid 1970s within a combination of re-
gional programmes and opportunistic screening. In 1976, an offi-
cial pilot study for cervical cancer screening was started in three
regions, covering 24% of the Dutch female population. However,
under political pressure, the screening programme was soon
extended to other regions, reaching almost nationwide coverage
around 1980. In 1988, a national screening programme was initi-
ated for women 35–54 years, who were offered screening 7 times
at 3 year intervals.14 In the early 1990s, evaluation of the screen-
ing programme in the Netherlands evidently indicated a subopti-
mal programme, in terms of both the organization and the cost of
screening the target population. In 1996, this programme was
therefore revised on the basis of extensive MISCAN simulation
model calculations. Since then women aged 30–60 years are
offered cytological screening at six 5 year intervals.15 The call-up
schedule is based on birth years and therefore a woman born in
1969, for example, will be called up in 1999 as a probable, but not
certain, 30-year-old at the time of the Pap smear.
Recently, it has been suggested that the age to initiate cervical
cancer screening should be even lower in the Netherlands, for two
reasons. Firstly, because of the increased risk of HPV-infection
because of earlier sex, the incidence of cervical cancer might be
rising in age group 25–29 years. Secondly, some believe that there
is an increase in the incidence of cervical cancer in age group 30–
44 years and therefore the screening age should be lowered to
detect preinvasive cervical lesions earlier.
One of the prerequisites for good screening practices is that
there must not be too much harm and the screening test should be
affordable. The affordability of a Pap smear is high: women do
not receive too much harm from it. However, a bulk of HPV infec-
tions will be found in young women aged 25–29 when they are
screened. Since most of these infections are transient, many
women will be referred unnecessarily to a gynaecologist for col-
poscopic treatment. Recommendations for the age to initiate cervi-
cal cancer screening should therefore be directed towards maxi-
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mum detection of early cervical cancer while avoiding the bulk of
transient HPV infections. Since there is no database available on
the incidence of HPV infections in The Netherlands, the aim of
this study was to answer the question of whether the target age for
cervical cancer screening should be lowered by determining (age




The Netherlands Cancer Registry (NCR) is nationwide since
1989, and therefore all cervical cancer cases diagnosed between 1
January 1989 and 31 December 2003 were selected from this pop-
ulation-based cancer registry. For the age group 25–39 years, inci-
dence data were also available for 2004 and 2005. The NCR
obtains notifications from the Pathology Automated Archive
(PALGA), Haematology Departments and Radiotherapy Depart-
ments of the hospitals as well as the National Registry of Hospital
Discharge Diagnoses. Death certificates are not available in an
identifiable form to the cancer registry because of privacy regula-
tions. All data are obtained from patient files in the hospital and
include identifying information (e.g., first letters of the name, date
of birth, sex, postal code) and tumour characteristics (e.g., date of
diagnosis, topography, morphology, stage). Topography and mor-
phology are coded according to the International Classification of
Diseases for Oncology (ICD-O), and the TNM classification is
used for staging the tumours.16,17
Although carcinoma in situ is registered in PALGA, it is not
included in the NCR, and consequently, only newly diagnosed
cases of invasive cervical cancer were included in this study.
Data on mortality from cervical cancer were derived from Sta-
tistics Netherlands (ICD-10 C53) and only available per 5 year
age group.18 Incidence and mortality rates per 100,000 person-
years were calculated. The Estimated Annual Percentage Change
(EAPC) was used as an estimate of the trend. Using calendar year
as a regression variable, a regression line was fitted to the natural
logarithm of the incidence rates, i.e., y 5 mx 1 b, where y 5
ln(rate) and x 5 calendar year. Then EAPC 5 100 3 (em 2 1).
Testing the hypothesis that the EAPC is equal to zero is equivalent
to testing the hypothesis that the slope of the regression line is
zero, using the t-distribution of m/SEm. The number of degrees of
freedom equals the number of calendar years minus 2. The stand-
ard error of m, i.e., SEm, is obtained from the fit of the regression
line. This calculation assumes that the rates increased/decreased at
a constant rate over the entire period. Therefore, joinpoint regres-
sion analysis was also used to identify points that indicate a statis-
tically significant change over time in the linear slope of the trend.
In joinpoint analyses, the join points where the rate changes signif-
icantly (increase or decrease) are computed. The analysis starts
with the minimum number of joinpoints, and tests whether one or
more joinpoints are statistically significant and should be added to
the model (up to 3 joinpoints). In the final model, each joinpoint
indicates a statistically significant change in trend. Significant
changes include changes in the slope of the trend. Joinpoint analy-
ses were performed using ‘Joinpoint software from the Surveil-
lance Research Program of the US National Cancer Institute.19
Results
Incidence
The incidence of cervical cancer appears to increase from age
29 onwards (Table I). Before age 29, the absolute number of cases
of cervical cancer varies annually between 0 and 9 per age year.
Because of the small numbers, incidence varied markedly between
different years of diagnosis, with potential decreases for ages 25,
26 and 28 years. In age group 25–29, the small increase was
mainly based on the incidence among 29-year-old women. No sig-
nificant rises in the incidence rates of cervical cancer were found.
However, significantly decreasing trends were seen for age groups
35–39 and 45–49 (p < 0.0001 and p 5 0.01, respectively). With
joinpoint analyses, we were not able to find any significant
changes in trends over time.
Mortality
The annual numbers fluctuate across the years, with a decreas-
ing trend for age groups 30–34 and 35–39 years (p 5 0.01 and p
5 0.04, respectively) (Table II). Significant rises in the incidence
rates of cervical cancer could not be found. However, compared to
all other age groups, age group 25–29 was the only group with a
(non-significant) increasing trend. We were not able to detect any
significant changes in the trends.
Discussion
Incidence of and mortality from cervical cancer in younger age
groups excluded from the screening programme are very low.
Mortality increased in age group 25–29 years but not significantly
TABLE I – NUMBER AND INCIDENCE RATES PER 100,000 PERSON-YEARS OF CERVICAL CANCER ACCORDING TO AGE IN THE NETHERLANDS, 1989–2005
Age at diagnosis, N (per 100,000) Incidence in 5 year age groups, N (per 100,000)
Year of diagnosis
25 26 27 28 291 25–29 30–34 35–39 40–442 45–492
1989 1 (0.8) 4 (3.2) 6 (4.8) 5 (4.0) 11 (8.9) 27 (4.3) 78 (13.2) 105 (18.7) 77 (13.6) 64 (14.9)
1990 6 (4.7) 6 (4.7) 8 (6.3) 7 (5.5) 8 (6.4) 35 (5.5) 71 (11.9) 109 (19.3) 102 (17.5) 55 (12.5)
1991 4 (3.2) 8 (6.2) 3 (2.3) 8 (6.3) 11 (8.7) 34 (5.3) 84 (13.8) 110 (19.3) 81 (13.9) 63 (13.4)
1992 2 (1.6) 3 (2.4) 7 (5.4) 7 (5.4) 4 (3.1) 23 (3.6) 87 (14.0) 120 (20.8) 80 (14.0) 76 (14.9)
1993 1 (0.8) 7 (5.6) 3 (2.4) 8 (6.2) 12 (9.2) 31 (4.9) 93 (14.8) 118 (20.2) 77 (13.7) 70 (12.9)
1994 3 (2.3) 2 (1.6) 2 (1.6) 7 (5.5) 5 (3.9) 19 (3.0) 72 (11.3) 110 (18.5) 75 (13.3) 89 (15.8)
1995 2 (1.6) 9 (7.0) 5 (4.0) 9 (7.2) 12 (9.4) 37 (5.8) 91 (14.1) 124 (20.5) 78 (13.8) 74 (12.8)
1996 3 (2.4) 6 (4.6) 5 (3.9) 3 (2.4) 11 (8.8) 28 (4.4) 97 (15.0) 116 (18.9) 73 (12.8) 62 (10.7)
1997 0 (0.0) 6 (4.8) 2 (1.5) 8 (6.2) 15 (11.9) 31 (4.9) 90 (14.0) 103 (16.5) 86 (14.9) 84 (14.8)
1998 3 (2.7) 6 (5.0) 5 (4.0) 6 (4.6) 20 (15.5) 40 (6.5) 89 (13.9) 96 (15.2) 93 (15.9) 77 (13.8)
1999 3 (2.9) 7 (6.2) 3 (2.5) 5 (4.0) 15 (11.5) 33 (5.5) 92 (14.6) 105 (16.5) 93 (15.6) 73 (13.1)
2000 1 (1.0) 0 (0.0) 2 (1.8) 4 (3.3) 6 (4.7) 12 (2.3) 93 (15.4) 100 (15.7) 72 (11.9) 64 (11.4)
2001 0 (0.0) 2 (2.0) 9 (8.4) 3 (2.6) 11 (9.0) 24 (4.6) 74 (11.8) 101 (15.2) 69 (11.2) 58 (10.2)
2002 3 (3.1) 1 (1.0) 6 (5.8) 5 (4.6) 12 (10.4) 26 (5.2) 70 (11.2) 79 (12.3) 85 (13.6) 66 (11.5)
2003 0 (0.0) 1 (1.0) 3 (3.0) 3 (2.9) 12 (11.1) 16 (3.7) 66 (11.0) 71 (11.1) 86 (13.6) 61 (10.5)
2004 3 (3.1) 4 (4.1) 6 (6.1) 5 (5.0) 9 (8.7) 27 (5.4) 75 (12.4) 96 (14.8) – –
2005 1 (1.0) 6 (6.1) 4 (4.1) 4 (4.1) 13 (13) 28 (5.7) 71 (12.3) 88 (13.6) – –
EAPC 21.4% 23.8% 1.2% 22.7% 3.6% 2.0% 20.7% 23.1% 20.9% 22.0%
p value 0.635 0.260 0.658 0.072 0.102 0.862 0.226 <0.001 0.195 0.012
1The column of age 29 is grey because the incidence rates may be biased by women who were diagnosed by participation in the screening pro-
gramme.–22004 and 2005 no data available for this age category.
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and mortality in this age group continues to be very low. The inci-
dence among women 29-year-old, which is higher than the inci-
dence for ages 25–28 separately, can be explained by the call-up
schedule and the reorganization of the screening programme. The
incidence for women 29-year-old started to rise in 1996, together
with the lowering of the screening age from 35 to 30 years. It is
known that the incidence of cancer increases after first onset of
screening activities, because prevalent cases will be detected then.
Also, because the call-up schedule is based on birth years a
woman will be called up as a probable, but not certain, 30-year-
old at the time of the Pap smear. If we adjust for this phenomenon
by considering all women who were actually 29 years old at the
time of diagnosis but were going to be 30 years old in the year of
diagnosis as 30 at diagnosis, the increase in 29-year-old women
becomes a non-significant decrease (EAPC, 24.2%; p 5 0.1).
Harm and affordability are important issues in policy making,
and lowering the screening age will have both psychological and
financial effects. In 2004 there were 97,000 25-year-old women in
The Netherlands. The mean attendance rate in The Netherlands
was 68% for age group 30–34 years (2003).20 Projecting this
attendance rate to 25-year-old women means that 64,000 25-year-
old women would have been screened if the target age of the
screening programme was 25–60 years. In The Netherlands, the
frequency of abnormal smears among 30-year-old women was
3.9%  LSIL in 2003.21 A study from the United States found
that 4% of women aged 25–29 years have HSIL or higher or to
have repeated borderline findings, which means that about 2,560
women (4% of 64,000) will be referred to a gynaecologist for col-
poscopic evaluation in The Netherlands.22 In addition to the anxi-
ety associated with undergoing a colposcopic examination, false-
positive results may cause persistent anxiety for many years. On
the other hand, a negative screening test result may reinforce an
unhealthy lifestyle.23 Also, there is the problem of overtreatment;
many women undergo conisation or loop electrosurgical excision
procedure (LEEP) for a CIN that may otherwise go into regression
because of its transient nature, especially in young women.
Although the side effects of these treatment procedures are mini-
mal, they should be avoided when not necessary.24 Another poten-
tial adverse effect of false-positive results is the expenses of fol-
low-up diagnostic procedures.
In contrast to The Netherlands, an increase in the incidence of
cervical cancer in young women was seen in other countries. In
Finland, a recent increase in the incidence of cervical cancer was
revealed among young women,25 which is underpinned by the his-
torical increase in HPV rates.26 There have been no changes in
organised screening or diagnostics as such. However, the average
number of sexual partners for Finnish women increased and the
average age at first intercourse of these women decreased.27 Also,
tobacco smoking has increased substantially among young Finnish
women during the 1980s.28 The findings of the Finnish study are
in agreement with those of other reports that there have been sig-
nificantly increased detection rates of preinvasive disease in the
younger age groups during recent decades.29,30 A study from Ice-
land confirms an increasing rate of preinvasive and invasive dis-
ease among younger women and indicates the benefit of starting
organised screening at 2–3 year intervals soon after age 20.31
They further state that in well-organised screening, overtreatment
of young women with low-grade lesions can easily be avoided.
Almost the same conclusions are drawn by a study from the
United Kingdom in which it was concluded that invasive cancer
rates in women aged 20–24 and 25–29 are low, but have not fallen
and remain higher than in 1974. Carcinoma in situ rates have
increased in women aged 20–24 and 25–29 years. In addition, the
authors state that giving accurate information about low-grade
lesions, together with promoting healthy lifestyles and safer sex,
empowers young women to look after their sexual health.
The absence of an increase in the incidence in The Netherlands
is not likely to be due to opportunistic screening in the lower age
groups. In general, opportunistic screening is very low in The
Netherlands, with only 33 per 1,000 women who are screened
spontaneously annually in age group 20–29 years.32 In The Neth-
erlands, unfortunately, there is no linkage of the cancer registry
with the cause-of-death registry. However, after 1970, there were
very few uterus ‘not otherwise specified cases of cancer in The
Netherlands and therefore the trends in mortality were affected
negligibly.33 Therefore, correction for this death cause certifica-
tion was not required, as was in many other European coun-
tries.34,35 In The Netherlands, the decrease in age at first inter-
course stopped about 10 years ago.36 However, the incidence of
HIV and other sexually transmitted infections has been increasing,
according to the latest surveillance data, and an increase in the
incidence of HPV infections may therefore also be expected.
Tobacco smoking, which is also a risk factor for cervical cancer,37
increased among women in The Netherlands during the 1950s and
1960s and started to decrease around 1970.38
Although lowering the screening age for the whole population
does not seem to improve the result of the screening programme
in The Netherlands, there might be specific risk groups for cervical
cancer at young age. Several studies have found more cervical
abnormalities among young women in certain immigrant popula-
tions who are known to have a higher primary risk.39,40 Increasing
their knowledge about HPV infection might result in higher
screening attendance rates.41 Another risk group are prostitutes
who run a higher risk of HPV infections and cervical intraepithe-
lial lesions.42 Finally, according to some studies, genital HPV
infections and cervical intraepithelial lesions are more common
among sexually abused than nonsexually abused girls.43 However,
since other studies indicate that the majority of anogenital HPV
infections among children are probably the result of nonsexual
horizontal transmission44 and because it is so difficult to prove
whether HPV infections are the result of involuntary sexual activ-
ity, it is almost impossible to classify these women as a risk group
and to treat them differently in terms of offering them smears at
younger age.
In conclusion, because increases in incidence and mortality
rates for cervical cancer could not be found in this study or could
just be attributed to earlier screening activity at age 29 since 1996,
further lowering the age for cervical cancer screening is not useful
at this time. Although mortality from cervical cancer is very low,
the number of life-years gained is high per woman for women
who are prevented from developing cervical cancer (20–40 years).
However, the disadvantages of lowering the screening age in
terms of ‘overtreatment and anxiety are high and seem therefore
to be disproportionate. The attendance rates of the current target
population should be optimized and the use of the HPV test should
TABLE II – MORTALITY FROM CERVICAL CANCER ACCORDING TO AGE
GROUP PER 100,000 PERSON-YEARS IN THE NETHERLANDS, 1989–2006
Mortality in 5 year age groups, N (per 100,000)
Year of diagnosis
25–29 30–34 35–39 40–44 45–49
1989 3 (0.5) 12 (2.0) 18 (3.2) 16 (2,8) 13 (3.0)
1990 4 (0.6) 10 (1.7) 17 (3.0) 15 (2.6) 16 (3.6)
1991 5 (0.8) 15 (2.5) 15 (2.6) 22 (3.8) 16 (3.4)
1992 4 (0.6) 6 (1.0) 18 (3.1) 15 (2.6) 17 (3.3)
1993 4 (0.6) 10 (1.6) 9 (1.5) 16 (2.8) 15 (2.8)
1994 1 (0.2) 7 (1.1) 17 (2.9) 15 (2.7) 12 (2.1)
1995 1 (0.2) 4 (0.6) 13 (2.2) 15 (2.7) 17 (2.9)
1996 2 (0.3) 7 (1.1) 14 (2.3) 9 (1.6) 19 (3.3)
1997 4 (0.6) 8 (1.2) 13 (2.1) 16 (2.8) 17 (3.0)
1998 0 (0.0) 6 (0.9) 14 (2.2) 14 (2.4) 21 (3.8)
1999 1 (0.2) 7 (1.1) 19 (3.0) 14 (2.4) 21 (3.8)
2000 4 (0.7) 9 (1.4) 11 (1.7) 21 (3.5) 28 (5.0)
2001 3 (0.6) 12 (1.9) 23 (3.5) 10 (1.6) 18 (3.2)
2002 4 (0.8) 5 (0.8) 11 (1.7) 9 (1.4) 16 (2.8)
2003 4 (0.8) 3 (0.5) 10 (1.5) 16 (2.5) 14 (2.4)
2004 0 (0.0) 4 (0.7) 17 (2.6) 17 (2.6) 11 (1.9)
2005 3 (0.6) 8 (1.4) 12 (1.9) 15 (2.3) 14 (2.3)
2006 2 (0.4) 3 (0.5) 10 (1.5) 13 (2.0) 16 (2.6)
EAPC 1.9% 25.1% 22.6% 22.1% 21.5%
p value 0.495 0.010 0.032 0.075 0.163
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be increased to improve triage and management.45 However,
although this is not evidence based, screening at younger age
might be advantageous for some high-risk groups. It seems better
to focus on improving the attendance rates among high-risk
groups, improving the quality of the smear and the validity of the
cytological diagnosis with possibly increase in the use of the HPV
test. The potential introduction of an HPV vaccine might make the
question of decreasing the start age of screening irrelevant.
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